Plus500 surges to new high after raising outlook

Plus500 reported FY2025 revenue of $792.4m (up 3%) and underlying EBITDA of $348.1m (up 2%), with non-OTC revenue exceeding $100m for the first time and non-OTC customer funds up 160% to over $0.9bn. The group finished the year with roughly $0.8bn cash, no debt, and announced $187.5m of shareholder returns ( $87.5m dividends and $100m buybacks), completed the acquisition of Mehta Equities in India and launched prediction-market and CME-clearing activity. Management said trading in FY2026 has started well, raised its outlook and expects performance ahead of market expectations, driving the stock to a new all-time high (jumping ~6.3%).

Analysis

Market structure: Plus500’s move into non‑OTC futures, prediction markets (as CME clearing provider) and India (Mehta) shifts it from a pure CFD/retail OTC player to a diversified retail + institutional clearing franchise. Immediate winners: Plus500 (higher fee diversity, $100m+ new non‑OTC revenue, >$0.9bn client funds) and CME (incremental clearing fees); losers: smaller pure‑CFD brokers (IGG, CMCX) facing share loss and margin pressure. A sustained shift would increase trading volumes in listed futures and FX venues and push more retail orderflow into cleared products, tightening liquidity spreads in short‑dated FX/indices instruments over 6–18 months.

Risk assessment: Key tail risks are regulatory clampdowns on prediction markets/CFDs (FCA/Indian regulators) and operational clearing failures or client fund issues; a single adverse ruling within 30–90 days could erase >20–30% of implied upside. Short‑term (days–weeks) catalysts are trading updates and integration milestones from Mehta; medium term (3–12 months) depends on retention of non‑OTC clients and margin profiles; long term (12–36 months) hinges on cross‑sell and CME relationship scaling. Hidden dependencies include interest income on client cash (sensitive to rates) and concentration of new business in a few geographies/products.

Trade implications: Bias constructive for Plus500 equity and for CME exposure to cleared retail flows; prefer directional long in Plus500 with defined risk via call spreads and a tactical long CME (NASDAQ:CME) on any pullback of 3–7% as optionality on clearing revenue. Relative trades: long PLUS vs short IG Group (LON:IGG) or CMC Markets (LON:CMCX) to express structural share shift; use small size (1–3% net). Use options to define downside: bought call spreads on PLUS 6–9 month expiries or collars if acquiring stock.

Contrarian angles: Market cheers growth and buybacks but may underprice regulatory/legal execution risk and margin dilution from lower‑margin clearing activities; ATH valuation already embeds acceleration — a 10–20% pullback should be treated as re‑rate risk not fundamental failure. Historical parallels: brokers that pivoted product mix (e.g., IG’s past shifts) saw volatile re‑ratings when regulation or margining costs hit; unintended consequence is higher capital tied to client cash and potential ROI dilution. Watch RN; if non‑OTC growth normalizes <+50% y/y in two consecutive quarters, de‑risk positions.

Key Decisions for Investors

• Establish a 2–3% long position in Plus500 (LON:PLUS) within 5 trading days; target 20–30% upside over 6–12 months, set a hard stop‑loss at 12% below entry and trim half at +25%.
• Initiate a relative‑value pair: long PLUS 2.0% / short IG Group (LON:IGG) 1.5% (or CMC Markets LON:CMCX 0.75%) to express non‑OTC share gains; close or rebalance if spread moves >15% in either direction within 3 months.
• Buy a defined‑risk call spread on PLUS: purchase Aug/Sep 2026 £48 call and sell £60 call (size = 0.5–1.0% portfolio notional) to capture upside funded by selling OTM call; if already long stock, consider a collar (buy 6‑month 12% OTM put) to cap downside.
• Reduce pure‑CFD broker exposure by 1–2% (IGG/CMCX) and redeploy into PLUS or cash; monitor FCA and Indian regulator announcements over next 30–90 days—if any restrictive guidance on prediction markets/CFDs is issued, exit or hedge immediately.